VNDA Stock Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.06 |
| 52 Week High | US$7.00 |
| 52 Week Low | US$3.30 |
| Beta | 0.78 |
| 1 Month Change | 6.56% |
| 3 Month Change | 7.98% |
| 1 Year Change | -37.92% |
| 3 Year Change | -75.30% |
| 5 Year Change | -75.82% |
| Change since IPO | -58.06% |
Recent News & Updates
Recent updates
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Apr 05Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
May 12Vanda Pharmaceuticals: What The Recent Partnership Entails
Oct 06Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics
Sep 29Vanda Pharmaceuticals Q2 Earnings Preview
Aug 02Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside
May 17Vanda: A Dual Growth And Value Player
Apr 11Analysts Are More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be
Feb 27Vanda: A Prudent Business With Upsides
Dec 30An Intrinsic Calculation For Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Suggests It's 32% Undervalued
Nov 01Is There An Opportunity With Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) 47% Undervaluation?
Jun 28It's Unlikely That The CEO Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Will See A Huge Pay Rise This Year
Jun 03Shareholder Returns
| VNDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | -3.9% | -3.1% |
| 1Y | -37.9% | -1.8% | 20.9% |
Return vs Industry: VNDA underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: VNDA underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| VNDA volatility | |
|---|---|
| VNDA Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VNDA has not had significant price volatility in the past 3 months.
Volatility Over Time: VNDA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 203 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VNDA fundamental statistics | |
|---|---|
| Market cap | US$237.05m |
| Earnings (TTM) | US$2.51m |
| Revenue (TTM) | US$192.64m |
93.1x
P/E Ratio1.2x
P/S RatioIs VNDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNDA income statement (TTM) | |
|---|---|
| Revenue | US$192.64m |
| Cost of Revenue | US$14.80m |
| Gross Profit | US$177.84m |
| Other Expenses | US$175.34m |
| Earnings | US$2.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 92.32% |
| Net Profit Margin | 1.30% |
| Debt/Equity Ratio | 0% |
How did VNDA perform over the long term?
See historical performance and comparison